Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pancreatitis Systemic Inflammatory Response Syndrome All of the following must be met for a patient to be randomized into the study: 1. The diagnosis of acute pancreatitis has been established by the presence of abdominal pain consistent with acute pancreatitis together with at least 1 of the following 2 1. Serum lipase > 3 times the upper limit of normal (ULN); 2. Characteristic findings of acute pancreatitis on abdominal imaging; 2. The diagnosis of SIRS has been established by the presence of at least two of the following four 1. Temperature < 36°C or > 38°C; 2. Heart rate > 90 beats/minute; 3. Respiratory rate >20 breaths/minute or arterial carbon dioxide tension (PaCO2) <32 mmHg; 4. White blood cell count (WBC) >12,000 mm3, or <4,000 mm3, or > 10% immature (band) forms; 3. At least one of the following is also present: 1. A peripancreatic fluid collection or a pleural effusion on a contrast-enhanced computed tomography (CECT) performed in the 12 hours before Consent or after Consent and before Randomization; 2. Abdominal examination documenting either abdominal guarding or rebound tenderness; 3. Hematocrit ≥44% for men or ≥40% for women; 4. The patient is ≥ 18 years of age; 5. Lack of pancreatic necrosis, pancreatic calcifications, pancreatic pseudocysts and no evidence for previous necrosectomy or pancreatic surgery identified by CECT performed in the 12 hours before Consent or after Consent and before Randomization; 6. A female patient of childbearing potential who is sexually active with a male partner is willing to practice acceptable methods of birth control for 180 days after the last dose of study drug. A female patient must not attempt to become pregnant for 180 days; 7. A male patient who is sexually active with a female partner of childbearing potential is willing to practice acceptable methods of birth control for 180 days after the last dose of study drug. A male patient must not donate sperm for 180 days; 8. The patient is willing and able to, or has a legal authorized representative (LAR) who is willing and able to, provide informed consent to participate, and to cooperate with all aspects of the protocol  Patients with any of the following conditions or characteristics must be excluded from randomizing: 1. Expected survival <6 months; 2. Suspected presence of cholangitis in the judgment of the treating physician; 3. The patient has a known history of: 1. Organ or hematologic transplant; 2. HIV, hepatitis B, or hepatitis C infection; 3. Chronic pancreatitis; 4. Current treatment with: 1. Chemotherapy; 2. Immunosuppressive medications or immunotherapy 3. Pancreatic enzyme replacement therapy; 4. Hemodialysis or Peritoneal Dialysis; 5. The patient is known to be pregnant or is nursing; 6. The patient has participated in another study of an investigational drug or therapeutic medical device in the 30 days before randomization; 7. Allergy to eggs or known hypersensitivity to any components of study drug